Table 2:
Demographic and laboratory characteristics for individuals with positive and negative functional assay status
| Trait | Functional assay negative1 |
Functional assay positive1 |
P-value2 |
|---|---|---|---|
| McMaster (n) | 2405 | 400 | |
| Age (mean (SD)) | 67.69 (14.70) | 68.29 (12.92) | 0.442 |
| Sex, female n (%) | 1037 (43.1) | 211 (52.8) | <0.001 |
| OD (mean (SD)) 3 | 0.33 (0.32) | 2.06 (0.61) | <0.001 |
| Surgery | 575 (38.3) | 78 (44.6) | 0.125 |
| Greifswald (n) | 3313 | 1203 | |
| Age (mean (SD)) | 66.67 (13.79) | 66.51 (13.37) | 0.719 |
| Sex, female n (%) | 1272 (38.6) | 495 (41.2) | 0.12 |
| OD (mean (SD)) 3 | 0.46 (0.45) | 1.67 (0.78) | <0.001 |
| Immunoglobulin A (IgA) 3 | 0.34 (0.38) | 0.72 (0.60) | <0.001 |
| Immunoglobulin M (IgM)3 | 0.50 (0.37) | 0.68 (0.43) | <0.001 |
| Tours (n) | 637 | 194 | |
| Age (mean (SD)) | 68.73 (12.12) | 67.08 (13.94) | 0.122 |
| Sex, female n (%) | 189 (29.7) | 105 (55.0) | <0.001 |
| OD (mean (SD)) 3 | 0.62 (0.60) | 2.46 (0.71) | <0.001 |
| Cardiopulmonary Bypass (CPB) Surgery4 | 637 (100.0) | 49 (25.5) | <0.001 |
| Platelet Count Before Heparin Therapy (1x109 platelets/L) | 213.27 (56.44) | 228.07 (95.87) | 0.014 |
Values represent mean (standard deviation) unless otherwise specified; n [%]: Total count in each category and the percentage of the overall sample size. OD indicates optical density.
ns indicate number of individuals with all relevant, non-missing variables, therefore totals in table may not sum to the total cohort as some patients contained specific variables with missingness.
P-values listed are from comparison of the trait between positive and negative functional assay status in each cohort
PF4/heparin antibody levels were determined using enzyme-linked immunosorbent assay (ELISA).
All functional assay negative patients underwent CPB surgery in the Tours cohort.